Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:31:15 EDT Sun 24 May 2026
Enter Symbol
or Name
USA
CA



Q:INCY - INCYTE CORPORATION - https://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q0.597.00·100.005.097.16-0.25-0.3879.884,34112,40697.30  98.21  96.04112.29  63.5116:20:00May 2015 min RT 2¢

Recent Trades - Last 10 of 12406
Time ETExPriceChangeVolume
16:20:00Q97.16-0.25135
16:18:37Q97.16-0.25303
16:15:33Q97.12-0.2915
16:15:33Q97.12-0.2970
16:15:33Q97.12-0.295
16:10:05Q97.16-0.251
16:10:05Q97.16-0.251
16:10:05Q97.16-0.251
16:10:05Q97.16-0.251
16:10:04Q97.16-0.251

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-20 08:00U:INCYNews ReleaseIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
2026-05-19 08:00U:INCYNews ReleaseIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
2026-05-12 09:30U:INCYNews ReleaseIncyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
2026-05-06 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 17:28U:INCYNews ReleaseIncyte Announces FDA Approval of Jakafi XR(TM) (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
2026-04-29 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2026-04-28 07:00U:INCYNews ReleaseIncyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
2026-04-28 07:00U:INCYNews ReleaseIncyte Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-21 10:00U:INCYNews ReleaseIncyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-04-09 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results
2026-04-07 07:30U:INCYNews ReleasePalvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
2026-04-02 07:01U:INCYNews ReleaseAdagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFsR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
2026-03-28 15:00U:INCYNews ReleaseIncyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-25 09:00U:INCYNews ReleaseIncyte Announces Executive Leadership Appointments
2026-03-20 10:00U:INCYNews ReleaseIncyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-17 07:30U:INCYNews ReleaseKnight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
2026-03-17 07:30U:INCYNews ReleaseKnight Therapeutics Announces Approval of Additional Indication for MINJUVI(TM) (tafasitamab) in Brazil
2026-03-06 16:42U:INCYNews ReleaseIncyte Announces the European Commission Approval of Zynyz(TM) (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
2026-02-27 08:11U:INCYNews ReleaseLilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
2026-02-17 10:48U:INCYNews ReleaseRegistration Momentum Builds Across the Oncology Pipeline